Compare Ginkgo Bioworks Holdings Inc (DNA) vs Gitlab Inc (GTLB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ginkgo Bioworks Holdings Inc vs Gitlab Inc — how do they compare? Ginkgo Bioworks Holdings Inc trades at $9.06 (market cap $590.53M), while Gitlab Inc trades at $33.32 (market cap $5.57B). The key difference: Gitlab Inc is far larger — about 9.4× Ginkgo Bioworks Holdings Inc's market cap, and Gitlab Inc is trading nearer its 52-week high, Ginkgo Bioworks Holdings Inc nearer its low. Which is the better fit depends on your goals.
| DNA | GTLB | |
|---|---|---|
Market Cap | $590.53M | $5.57B |
Sector | Health | Technology |
52-Week High | $16.14 | $51.04 |
52-Week Low | $5.48 | $19.42 |
Enterprise Value | $627.78M | $4.31B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DNA trades at $9.05, down 0.44% on the day, reflecting ongoing investor caution. The technical outlook is bearish, while fundamentals show significant losses with a net income margin of -201.05% and negative cash flows. Recent earnings have been mixed, missing estimates in two of the last three quarters. Analyst sentiment is divided, with a slight lean toward buy ratings amid high volatility and operational challenges.
The outlook remains challenging due to persistent losses and cash burn, though analyst coverage suggests potential long-term value. Key risks include execution missteps and intense competition in biotechnology. Investment appeal hinges on future profitability improvements and successful business model execution.
GitLab (GTLB) trades at $33.47, up 3.24% today, with a bullish technical signal from moving averages and a consensus analyst price target of $31.93. The company reported strong revenue growth to $759.25 million in 2025, though it remains unprofitable with a net margin of -2.49%. Recent news highlights its leadership in DevSecOps and AI-driven platform expansions, including a collaboration with Google Cloud.
The outlook is mixed; robust revenue growth and strategic positioning in AI and DevSecOps offer upside, but profitability challenges and high valuation multiples pose risks. Analyst sentiment is cautious with a majority hold rating, reflecting concerns over near-term execution versus long-term potential in the enterprise software market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →About Gitlab Inc
GitLab Inc operates on an all-remote model. The company is a technology company whose primary offering is GitLab, a complete DevOps platform delivered as a single application. GitLab is used by a wide range of organizations. The company also provides related training and professional services. GitLab is offered on both self-managed and software-as-a-service (SaaS) models. The principal markets for GitLab are currently located in the United States, Europe, and Asia Pacific. The company is focused on accelerating innovation and broadening the distribution of its platform to companies across the world.
Read more on GTLB →
